MorphoSys to Present at Upcoming Investor Conferences
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Present at Upcoming Investor Conferences
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present
at the following conferences:
Bryan Garnier 4th Healthcare Conference
Date: November 14, 2016
Venue: Paris, France
Presenter: Dr. Claudia Gutjahr-Löser & Anke Linnartz
Head of Corporate Communications & IR
HSBC Healthcare Day 2016
Date: November 17, 2016
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
Eigenkapitalforum 2016
Date: November 21, 2016
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
13th Kempen & Co Life Sciences Conference
Date: November 23, 2016
Venue: London, UK
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
dbAccess Pharmaceutical & Healthcare Corporate Day
Date: December 1, 2016
Venue: London, UK
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
American Society of Hematology (ASH) Annual Meeting 2016
Date: December 5, 2016
MorphoSys will hold an Investor & Analyst Event at the 2016 ASH Annual Meeting.
Clinical data published at the medical conference will be presented.
A PDF version of all presentations will be provided at www.morphosys.com.
The link to webcasts will be filed under www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties, Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated,
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/2056514/770293.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 14.11.2016 - 10:00 Uhr
Sprache: Deutsch
News-ID 506622
Anzahl Zeichen: 4535
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Present at Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
